Last 48 quarters of trend data · Healthcare · Medical Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 57.77 | 40.72 | 53.85 | 30.33 | 133.20 | 38.88 | 34.92 | 29.70 | 28.47 | 3.22 | 37.86 | 41.19 | 31.25 | 27.49 | 47.16 | 36.93 | 28.70 | 37.56 | 36.57 | 49.88 | 61.11 |
| — | +4.7% | +54.2% | +2.1% | +367.8% | +1109.2% | -7.8% | -27.9% | -8.9% | -88.3% | -19.7% | +11.5% | +8.9% | -26.8% | +29.0% | -26.0% | -53.0% | -28.3% | +10.2% | +28.8% | +31.3% | |
| P/S Ratio | 8.81 | 7.27 | 7.50 | 7.05 | 7.90 | 7.33 | 7.50 | 7.54 | 7.89 | 7.29 | 10.07 | 10.85 | 9.14 | 8.49 | 11.11 | 8.66 | 8.52 | 9.78 | 10.84 | 13.81 | 15.39 |
| — | -0.9% | +0.0% | -6.5% | +0.2% | +0.6% | -25.5% | -30.5% | -13.7% | -14.2% | -9.4% | +25.4% | +7.2% | -13.2% | +2.5% | -37.3% | -44.6% | -28.3% | -8.5% | +27.3% | +27.3% | |
| P/B Ratio | 5.79 | 4.55 | 4.87 | 4.50 | 4.80 | 4.46 | 4.34 | 4.18 | 4.34 | 4.11 | 7.44 | 8.03 | 6.89 | 6.28 | 8.93 | 8.34 | 7.92 | 8.30 | 10.03 | 12.68 | 14.03 |
| — | +1.9% | +12.4% | +7.7% | +10.4% | +8.7% | -41.7% | -48.0% | -36.9% | -34.6% | -16.7% | -3.6% | -13.0% | -24.4% | -10.9% | -34.2% | -43.6% | -35.7% | -21.1% | +11.8% | +11.3% | |
| P/FCF | 41.30 | 24.60 | 22.33 | — | 35.08 | 22.06 | 47.72 | 47.46 | — | 30.84 | 48.78 | — | 330.54 | 29.64 | — | 50.02 | 59.34 | 51.60 | 51.53 | 83.97 | 73.16 |
| — | +11.5% | -53.2% | — | — | -28.5% | -2.2% | — | — | +4.1% | — | — | +457.1% | -42.6% | — | -40.4% | -18.9% | +36.0% | +44.3% | +23.7% | +45.4% | |
| EV / EBITDA | 30.18 | 34.49 | 22.26 | 20.14 | 28.67 | 23.46 | 23.14 | 23.27 | 29.12 | 23.69 | 33.93 | 36.30 | 29.12 | 27.07 | 35.17 | 28.30 | 25.41 | 27.19 | 31.47 | 38.61 | 50.82 |
| — | +47.0% | -3.8% | -13.5% | -1.5% | -1.0% | -31.8% | -35.9% | -0.0% | -12.5% | -3.5% | +28.2% | +14.6% | -0.5% | +11.7% | -26.7% | -50.0% | -31.1% | -3.9% | +27.1% | +43.1% | |
| EV / EBIT | 34.58 | 32.66 | 24.08 | 24.38 | 130.99 | 31.26 | 29.97 | 23.14 | 23.45 | 23.14 | 35.48 | 38.53 | 31.20 | 26.77 | 51.99 | 31.58 | 24.98 | 31.33 | 31.71 | 42.18 | 54.11 |
| — | +4.5% | -19.6% | +5.4% | +458.7% | +35.1% | -15.5% | -39.9% | -24.9% | -13.6% | -31.8% | +22.0% | +24.9% | -14.5% | +64.0% | -25.1% | -53.8% | -30.3% | +7.6% | +26.0% | +35.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.1% | 78.5% | 77.6% | 78.2% | 78.3% | 77.9% | 77.6% | 78.7% | 78.9% | 80.6% | 78.5% | 78.2% | 80.2% | 78.1% | 79.1% | 75.4% | 78.1% | 78.7% | 79.2% | 77.1% | 76.6% |
| — | +0.8% | -0.1% | -0.6% | -0.8% | -3.4% | -1.1% | +0.5% | -1.6% | +3.2% | -0.7% | +3.8% | +2.7% | -0.8% | -0.1% | -2.3% | +1.9% | +2.2% | +3.8% | +1.1% | +1.8% | |
| Operating Margin | 27.0% | 17.4% | 29.8% | 31.2% | 23.6% | 27.4% | 28.1% | 27.9% | 22.6% | 25.9% | 26.3% | 26.7% | 28.2% | 27.9% | 28.6% | 27.6% | 30.4% | 32.4% | 31.2% | 32.5% | 27.2% |
| — | -36.3% | +6.1% | +11.7% | +4.6% | +5.7% | +6.9% | +4.5% | -19.9% | -7.1% | -8.0% | -3.1% | -7.3% | -14.0% | -8.3% | -15.1% | +11.6% | +4.2% | -4.8% | +1.1% | -10.5% | |
| Net Margin | 17.7% | 17.9% | 13.9% | 23.1% | 5.8% | 18.7% | 21.5% | 25.3% | 27.8% | 226.7% | 26.2% | 26.5% | 29.2% | 31.0% | 23.7% | 23.3% | 29.5% | 26.0% | 29.6% | 27.9% | 25.2% |
| — | -4.4% | -35.4% | -8.9% | -79.1% | -91.7% | -18.0% | -4.2% | -4.7% | +632.4% | +10.7% | +13.4% | -1.1% | +18.9% | -19.9% | -16.3% | +17.2% | +0.3% | -16.8% | +0.2% | -2.9% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.5% | 2.8% | 2.3% | 3.7% | 0.9% | 2.8% | 3.2% | 3.5% | 3.9% | 35.9% | 5.0% | 5.1% | 5.5% | 5.8% | 4.9% | 5.7% | 6.6% | 5.6% | 6.9% | 6.4% | 5.9% |
| — | +1.4% | -27.5% | +4.2% | -77.3% | -92.2% | -35.9% | -30.2% | -28.8% | +514.1% | +0.8% | -11.8% | -17.0% | +3.4% | -28.8% | -10.3% | +12.4% | -11.3% | -31.0% | -12.7% | -16.4% | |
| ROA | 8.0% | 2.2% | 1.8% | 2.8% | 0.7% | 2.2% | 2.5% | 2.7% | 3.0% | 26.6% | 3.7% | 3.7% | 3.9% | 4.2% | 3.5% | 4.0% | 4.7% | 4.0% | 4.8% | 4.4% | 4.0% |
| — | +0.9% | -28.5% | +2.6% | -77.2% | -91.8% | -32.2% | -25.5% | -25.0% | +535.4% | +5.4% | -8.3% | -16.1% | +4.1% | -27.9% | -9.0% | +16.9% | -6.3% | -26.7% | -5.7% | -8.7% | |
| ROIC | 15.5% | 2.6% | 4.6% | 4.6% | 3.4% | 3.9% | 4.1% | 3.8% | 3.3% | 4.0% | 4.1% | 4.1% | 4.4% | 4.3% | 4.6% | 5.2% | 5.4% | 5.8% | 5.9% | 5.9% | 5.2% |
| — | -33.0% | +11.3% | +20.8% | +4.2% | -1.6% | -1.1% | -7.1% | -25.1% | -7.2% | -10.9% | -20.8% | -19.2% | -25.7% | -21.0% | -11.1% | +3.2% | -12.7% | -24.5% | -17.5% | -23.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.12 | 0.12 |
| — | -6.3% | -0.8% | -0.8% | -1.9% | -6.7% | -28.3% | -29.5% | -31.8% | -28.4% | -13.0% | -14.2% | -14.4% | -7.0% | -7.6% | -3.6% | +0.6% | -10.5% | -13.8% | -20.4% | -22.1% | |
| Debt / EBITDA | 0.39 | 2.05 | 1.25 | 1.27 | 1.71 | 1.51 | 1.50 | 1.62 | 1.97 | 1.84 | 1.71 | 1.77 | 1.74 | 1.80 | 1.68 | 1.55 | 1.53 | 1.46 | 1.45 | 1.44 | 1.72 |
| — | +35.8% | -16.4% | -22.0% | -13.3% | -17.8% | -12.6% | -8.6% | +13.2% | +1.8% | +1.8% | +14.8% | +13.7% | +23.2% | +15.7% | +7.3% | -10.9% | -4.2% | +4.9% | -9.9% | -0.5% | |
| Current Ratio | 3.72 | 4.60 | 4.52 | 4.42 | 3.72 | 4.00 | 4.68 | 4.45 | 4.18 | 3.46 | 3.71 | 3.75 | 3.38 | 3.28 | 3.15 | 3.01 | 3.03 | 3.83 | 3.37 | 3.41 | 3.08 |
| — | +14.8% | -3.4% | -0.8% | -11.0% | +15.7% | +26.2% | +18.6% | +23.7% | +5.4% | +17.7% | +24.7% | +11.5% | -14.2% | -6.4% | -11.8% | -1.7% | +5.2% | -10.2% | -11.2% | -10.9% | |
| Quick Ratio | 3.09 | 3.86 | 3.77 | 3.63 | 3.09 | 3.29 | 3.87 | 3.66 | 3.45 | 2.89 | 2.87 | 2.67 | 2.62 | 2.45 | 2.30 | 2.17 | 2.17 | 3.00 | 2.60 | 2.64 | 2.38 |
| — | +17.5% | -2.5% | -0.8% | -10.4% | +13.6% | +34.9% | +37.0% | +31.8% | +18.1% | +24.5% | +23.2% | +20.7% | -18.4% | -11.5% | -18.1% | -8.6% | +4.5% | -10.0% | -8.2% | -7.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 423.45 | 437.10 | 314.58 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EW stock.
Edwards Lifesciences Corporation's current P/E is 57.8x. The average P/E over the last 4 quarters is 64.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Edwards Lifesciences Corporation's current operating margin is 27.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Edwards Lifesciences Corporation's business trajectory between earnings reports.